Ablynx and Boehringer Ingelheim continue collaboration into Alzheimer's disease
A pioneer in the discovery and development of a novel class of antibody-derived therapeutic proteins has extended its collaboration with Boehringer Ingelheim on Alzheimer's disease.
A pioneer in the discovery and development of a novel class of antibody-derived therapeutic proteins has extended its collaboration with Boehringer Ingelheim on Alzheimer's disease.
Research funding for the study, which uses Ablynx's Nanobodies tool, has been extended for another year.
Both parties started collaborating in January 2007, after entering into a $265m (Euro 179m) worldwide research and licensing agreement to discover and develop new therapies for Alzheimer's disease.
The agreement also included a joint research programme with Ablynx scientists. Boehringer Ingelheim will be solely responsible for the development, manufacture and commercialisation of any products resulting from the collaboration. As part of the collaboration, Ablynx, which is based in Ghent, Belgium, received an upfront fee and will receive development and commercial milestones as well as undisclosed royalties based on net sales.
"We are very pleased with the progress that has been made in our joint Alzheimer's disease programme with Boehringer Ingelheim," said Ablynx chairman and ceo Dr Edwin Moses. "We look forward to continue working together with Boehringer Ingelheim in this medical area which urgently requires an innovative approach."